Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cancer Frequencies and Screening in Individuals With Down Syndrome: A Comprehensive Nationwide Cross-Sectional Analysis.

JCO global oncology·2026

Same author

Computed Tomography-Based Assessment of Sarcopenia and Disease Progression in Pancreatic Ductal Adenocarcinoma: A Radiomics and Machine Learning Approach.

Gastroenterology research·2026

Same author

ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer.

Cancer research·2026

Same author

[Prevention in Gastroenterology].

Zeitschrift fur Gastroenterologie·2026

Same author

Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: the STOPSTORM.eu study.

European heart journal·2026

Same author

A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.

Scientific reports·2026

Search research articles

Related Experiment Video

Updated: Mar 14, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Radiation therapy in cholangiocellular carcinomas.

Thomas B Brunner¹, Thomas Seufferlein²

¹Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, Freiburg, Germany; German Cancer Consortium (DKTK), Freiburg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.

Best Practice & Research. Clinical Gastroenterology

|September 21, 2016

Summary

Adjuvant chemoradiotherapy is a key treatment for biliary tract cancers like cholangiocarcinoma, with stereotactic body radiotherapy (SBRT) emerging as a powerful alternative for definitive treatment, improving local control.

Keywords:

Adjuvant Chemoradiothearpy Chemotherapy Cholangiocarcinoma Definitive

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Mar 14, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

Oncology
Radiation Oncology
Surgical Oncology

Background:

Cholangiocarcinoma (CCA) presents therapeutic challenges due to its varied locations within the biliary tract.
Local relapse post-surgery is a significant clinical problem in CCA management.
Adjuvant chemoradiotherapy has been investigated to improve outcomes.

Purpose of the Study:

To review the current evidence for adjuvant and definitive treatment strategies in cholangiocarcinoma.
To highlight the role of chemoradiotherapy and stereotactic body radiotherapy (SBRT) in managing CCA.
To identify areas for future clinical trial development.

Main Methods:

Review of clinical trial data, focusing on the SWOG-S0809 trial for extrahepatic CCA and gallbladder cancer.
Comparison of conventionally fractionated radiotherapy with SBRT for definitive treatment.
Evaluation of sequential chemotherapy combinations.

Main Results:

The SWOG-S0809 regimen represents a high level of evidence for adjuvant chemoradiotherapy in specific CCA subtypes.
Stereotactic body radiotherapy (SBRT) offers an alternative to chemoradiotherapy for definitive treatment, enhancing local control through higher radiation doses.
Sequential chemotherapy regimens are commonly used.

Conclusions:

While surgery is primary, adjuvant chemoradiotherapy and SBRT are crucial in improving outcomes for cholangiocarcinoma.
SBRT shows promise as a definitive treatment option, offering improved local tumor control.
Cholangiocarcinoma remains an orphan disease, necessitating further clinical trials to strengthen the evidence base.